FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 918 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Teclistamab September 11, 2026 ΚΑΡΚΙΝΟΣ ΤΩΝ ΟΣΤΩΝ February 10, 2019 ESMO Sarcoma & GIST Symposium 2022, 31 January – 2 February January 18, 2022 NHS lung cancer patients in England to get early access to... September 9, 2021 Load more HOT NEWS Woman with Breast Cancer May Have Saved Her Twin’s Life by... Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —... Why the voices of people affected by cancer are critical to... FDA Approves Atezolizumab for BRAF V600 Mutation Positive Unresectable or Metastatic...
